FSNUY - Fresenius SE & Co. KGaA

Other OTC - Other OTC Delayed Price. Currency in USD
12.54
-0.01 (-0.10%)
At close: 3:45PM EDT
Stock chart is not supported by your current browser
Previous Close12.55
Open12.62
Bid0.00 x 0
Ask0.00 x 0
Day's Range12.52 - 12.65
52 Week Range11.00 - 20.41
Volume21,433
Avg. Volume18,603
Market Cap33.516B
Beta (3Y Monthly)1.21
PE Ratio (TTM)11.88
EPS (TTM)1.06
Earnings DateN/A
Forward Dividend & Yield0.22 (1.78%)
Ex-Dividend Date2019-05-20
1y Target EstN/A
Trade prices are not sourced from all markets
  • Fresenius investment in emerging markets will take a while to pay off, CEO says
    CNBC Videos3 months ago

    Fresenius investment in emerging markets will take a while to pay off, CEO says

    Stephan Sturm, CEO of German health care firm Fresenius, breaks down the sales growth the company saw in the first quarter of 2019.

  • Investors Who Bought Fresenius SE KGaA (FRA:FRE) Shares Three Years Ago Are Now Down 30%
    Simply Wall St.8 days ago

    Investors Who Bought Fresenius SE KGaA (FRA:FRE) Shares Three Years Ago Are Now Down 30%

    For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...

  • GuruFocus.com11 days ago

    Why Fresenius Is the Initial Winner From Trump's Kidney Disease Overhaul

    Fresenius appears better prepared than DaVita for market transition from outpatient to home dialysis caused by the Trump kidney initiative Continue reading...

  • These European companies benefit from high health-care prices in the U.S.
    MarketWatch26 days ago

    These European companies benefit from high health-care prices in the U.S.

    European health-care companies have a special advantage in the U.S. — high prices for their products and services. Nicole Kornitzer, a portfolio manager of the Buffalo International Fund, discussed broad health-care trends and named three European companies well-positioned to benefit from them. Kornitzer has been a co-manager of the Buffalo International Fund (BUFIX) with her cousin Bill Kornitzer since 2009.

  • Fresenius SE & Co. KGaA (FRA:FRE): The Best Of Both Worlds
    Simply Wall St.27 days ago

    Fresenius SE & Co. KGaA (FRA:FRE): The Best Of Both Worlds

    I've been keeping an eye on Fresenius SE & Co. KGaA (FRA:FRE) because I'm attracted to its fundamentals. Looking at...

  • A Look At Fresenius SE & Co. KGaA's (FRA:FRE) Exceptional Fundamentals
    Simply Wall St.27 days ago

    A Look At Fresenius SE & Co. KGaA's (FRA:FRE) Exceptional Fundamentals

    Fresenius SE & Co. KGaA (FRA:FRE) is a stock with outstanding fundamental characteristics. When we build an investment...

  • Reuters2 months ago

    INSIGHT-Will Europe's clampdown on faulty medical devices hurt patients?

    When a Californian company founded by a U.S. veteran wounded in Afghanistan sought to register a new medical device this year, it turned to Europe before the United States. "Now it has flipped," said Bill Colone, CEO of San Clemente-based Spinal Singularity, which hopes to launch a 'smart' catheter for men with spinal injuries or disease early next year after squeezing in its application under the old European rules. Colone is part of a chorus of industry voices warning that a switch to stricter European rules governing medical devices, due to come into force a year from now, will slow or even halt the release of products in Europe that could transform patients' lives.

  • Boasting A 14% Return On Equity, Is Fresenius SE & Co. KGaA (FRA:FRE) A Top Quality Stock?
    Simply Wall St.2 months ago

    Boasting A 14% Return On Equity, Is Fresenius SE & Co. KGaA (FRA:FRE) A Top Quality Stock?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Moody's2 months ago

    Fresenius Finance Ireland II Plc -- Moody's announces completion of a periodic review of ratings of Fresenius SE & Co. KGaA

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius SE & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • What To Know Before Buying Fresenius SE & Co. KGaA (FRA:FRE) For Its Dividend
    Simply Wall St.2 months ago

    What To Know Before Buying Fresenius SE & Co. KGaA (FRA:FRE) For Its Dividend

    Is Fresenius SE & Co. KGaA (FRA:FRE) a good dividend stock? How would you know? Dividend paying companies with growing...

  • Reuters2 months ago

    Fresenius talking to potential suitors about sale of blood transfusion business - sources

    Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday. Fresenius has hired Goldman Sachs to explore the sale, the people said.

  • Zacks Small Cap Research2 months ago

    CTSO: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust

    Q1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. CytoSorbents (CTSO) reported financial results for their first quarter ending March 31st and provided a business update. While grant revenue was inline with expectations, product sales were a relative dud.

  • Reuters3 months ago

    Fresenius makes solid start to year after turbulent 2018

    Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

  • Associated Press3 months ago

    Fresenius: 1Q Earnings Snapshot

    On a per-share basis, the Bad Homburg, Germany-based company said it had net income of 50 cents. Earnings, adjusted for non-recurring costs, came to 59 cents per share. The dialysis services provider posted ...

  • Fresenius SE & Co. KGaA (FRA:FRE): Immense Growth Potential?
    Simply Wall St.3 months ago

    Fresenius SE & Co. KGaA (FRA:FRE): Immense Growth Potential?

    Looking at Fresenius SE & Co. KGaA's (FRA:FRE) earnings update in December 2018, analyst forecasts seem fairly subdued, with earnings expected to grow by -7.2% in the upcoming y...

  • What Kind Of Shareholder Owns Most Fresenius SE  Co. KGaA (FRA:FRE) Stock?
    Simply Wall St.3 months ago

    What Kind Of Shareholder Owns Most Fresenius SE Co. KGaA (FRA:FRE) Stock?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Every investor in Fresenius SE & Co. KGaA (FRA:FRE) should be aware of the most powerful shareholder groups. Insiders of...

  • Cara Therapeutics Inc (CARA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Cara Therapeutics Inc (CARA) Q4 2018 Earnings Conference Call Transcript

    CARA earnings call for the period ending December 31, 2018.

  • Reuters5 months ago

    Trade talks keep European shares afloat as Sainsbury's, Swedbank sink

    Trade talks between the world's two biggest economies helped European shares rise on Wednesday, while the threat of a blocked merger sank shares in British supermarket Sainsbury's and a money laundering scandal hit Swedbank. Germany's trade-sensitive DAX led the way with a 0.8 percent gain and the pan-European STOXX 600 rose 0.7 percent after U.S. President Donald Trump said on Tuesday that trade talks with China were going well.

  • Reuters5 months ago

    Fresenius flags faster earnings growth from 2020 after investment

    Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday. Investors, who were disappointed last year after the company trimmed its guidance in October and abandoned in 2020 targets in December, were heartened by the outlook and the prospect of a 7 percent increase in the dividend to 0.80 euros per share. "2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies," Chief Executive Stefan Sturm said in a statement.

  • Reuters5 months ago

    U.S. approves Fresenius purchase of NxStage

    The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday. To win approval for the $2 billion deal, the companies agreed to sell NxStage's bloodline tubing set business, the agency said. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency said.

  • How Should Investors React To Fresenius SE & Co. KGaA’s (FRA:FRE) CEO Pay?
    Simply Wall St.6 months ago

    How Should Investors React To Fresenius SE & Co. KGaA’s (FRA:FRE) CEO Pay?

    Want to help shape the future of investing tools? Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued Read More...

  • Fresenius SE & Co. KGaA (FRA:FRE): A Fundamentally Attractive Investment
    Simply Wall St.6 months ago

    Fresenius SE & Co. KGaA (FRA:FRE): A Fundamentally Attractive Investment

    Attractive stocks have exceptional fundamentals. In the case of Fresenius SE & Co. KGaA (FRA:FRE), there's is a notable dividend-paying company with a a great history of performance, trading at Read More...